UroFollow试验:低/中危膀胱癌标志物引导随访与膀胱镜随访的前瞻性随机对照结果
UroFollow试验将214例低/中危非肌层浸润性膀胱癌患者随机分为标准随访组和每6个月标志物引导随访组,比较诊断准确性以评估非劣效性(界值<20%)。标志物组灵敏度81.5%低于标准组96.5%(p=0.1),但未遗漏进展期肿瘤,且膀胱镜操作次数显著减少(148次 vs 589次,p<0.001)。结论认为阴性3个月膀胱镜后每6个月标志物随访在该队列中是安全的。
要点
- 标志物引导随访灵敏度81.5% vs 标准随访96.5%,差异未达统计学显著(p=0.1)。
- 标志物组膀胱镜操作次数显著少于标准组(148 vs 589次,p<0.001)。
- 两组均未遗漏肿瘤分期或分级进展,标志物随访在本队列中安全可行。
核心结论
- 在低/中危NMIBC患者中,阴性3个月膀胱镜后每6个月标志物引导随访是安全的,可显著减少膀胱镜操作次数。
研究设计与样本
- 前瞻性随机对照试验,纳入214例Ta低级别和高级别(G1-2)NMIBC患者,随机分为标准随访组(n=109)和标志物引导随访组(n=105)。
- 标志物引导方案包括尿液标志物和超声算法,仅算法阳性者行白光膀胱镜;中位随访2.4年。
主要发现
- 标准随访组和标志物组分别诊断30例和29例肿瘤复发。
- 灵敏度标准组96.5% vs 标志物组81.5%(p=0.1),分别遗漏1例和5例Ta低级别肿瘤。
- 标准随访组行589次白光膀胱镜,标志物组行148次(p<0.001)。
- 在五种其他标志物中,Bladder EpiCheck和Xpert膀胱癌监测仪表现与算法相似。
关键数值与推荐
- 非劣效性界值为<20%。
- 每6个月进行标志物引导随访(尿液标志物+超声算法)。
- 阴性3个月白光膀胱镜后,仅算法阳性者行膀胱镜;推荐3年时对无复发患者行研究终点膀胱镜。
临床怎么用
- 对于低/中危NMIBC患者,在阴性3个月膀胱镜后可采用每6个月标志物引导随访以减少膀胱镜操作。
- 标志物随访可能遗漏部分Ta低级别肿瘤,但未遗漏进展期肿瘤,需结合临床评估。
局限性
- 样本量较小(214例),随访时间较短(中位2.4年)。
- 标志物引导随访灵敏度低于标准随访,差异未达统计学显著,需更大样本验证。
- 其他尿液标志物的潜在应用需前瞻性确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: A growing body of evidence suggests that the intensity of current follow-up in non-muscle-invasive bladder cancer (NMIBC) patients greatly exceeds clinical necessities. The UroFollow trial investigated the diagnostic accuracy of marker-based follow-up in patients with low/intermediate-risk NMIBC against the standard of care (SOC) for noninferiority (margin: <20%). METHODS: Patients with Ta low- and high-grade (G1-2) NMIBC were randomized to the SOC or 6-monthly marker-based follow-up (algorithm comprising urine markers and ultrasound; marker-based surveillance regimen [MA]). After a negative 3-mo cystoscopy (white light cystoscopy [WLC]), only patients with a positive algorithm underwent WLC in the MA. End-of-study WLC was recommended at 3 yr to recurrence-free patients. Simultaneously, several innovative urine markers were examined. KEY FINDINGS AND LIMITATIONS: In total, 214 patients were randomized to the SOC (n = 109) and MA (n = 105). The median follow-up was 2.4 yr; 30 and 29 cases of tumor recurrence were diagnosed in the SOC and MA arms, respectively. Sensitivity was 96.5% versus 81.5% (p = 0.1), with one and five Ta low-grade tumors being overlooked in the SOC and MA patients, respectively. No tumor progressing in stage or grade was missed. A total of 589 WLC procedures were performed in the SOC and 148 in the MA arm (p < 0.001). Among five other markers (ADX-Bladder, CellDetect, Bladder EpiCheck, UBC rapid, and Xpert bladder cancer monitor [BC-M]), Bladder EpiCheck and the Xpert BC-M showed similar performance to the algorithm. CONCLUSIONS AND CLINICAL IMPLICATIONS: UroFollow is the first urine marker-based randomized trial in low/intermediate-risk NMIBC patients. We conclude that 6-monthly marker-based follow-up after negative 3-mo WLC is safe in this cohort. Results of contemporary urine markers suggest that their potential for use in marker-based surveillance, however, requires prospective confirmation.
引用
- Schmitz-Dräger BJ, Bismarck E, Roghmann F, et al. Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder Cancer. Eur Urol Oncol. 2025. PMID: 40340174. doi:10.1016/j.euo.2025.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。